Clinical Trial Update: Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study assessing the absolute bioavailability of BMS-626529 after oral and intravenous dosing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• BMS-626529

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus | Phase 1 | Status: COMPLETED